EUVIMEDEUVIMED entdecken
Crossref

Long‐Term Excretion of Roxadustat in Urine

Tim Sobolevsky iD, Matthew Fedoruk iD, Frank Dellanna, Hans Geyer, Brian Ahrens, Mario Thevis iD

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Tim Sobolevsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, UCLA Olympic Analytical Laboratory, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Glycine, Isoquinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Roxadustat (FG‐4592), an orally active hypoxia‐inducible factor prolyl hydroxylase stabilizer, has been shown to enhance erythropoiesis by increasing endogenous erythropoietin. It is indicated for the treatment of anemia and chronic kidney disease and is approved for clinical use in several countries, including the European Union, Japan and others. Due to its reasonably anticipated performance‐enhancing effect in athletes, roxadustat is prohibited for use in sports at all times. A few cases of adverse analytical findings in routine doping controls have been reported worldwide, some of which were claimed to be the result of contaminated dietary supplements. The present study offers new data demonstrating the long‐term excretion pattern of roxadustat. Even after a single‐dose administration, roxadustat can remain detectable in urine for 8 months, albeit at very low concentrations (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycineIsoquinolinesHumansMaleDoping in SportsAdultAnemiaSubstance Abuse DetectionFemaleTime Factors

Stichwörter der Autor:innen

FG‐4592dopinglong‐term excretionpharmacokineticsroxadustat

Substanzen

GlycineroxadustatIsoquinolines

Autor:innen und Institutionen

  • Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, UCLA Olympic Analytical Laboratory, Los Angeles, California, USA.
  • Science and Research Department, US Anti-Doping Agency, Colorado Springs, Colorado, USA.
  • Department of Nephrology and Dialysis, MVZ DaVita Rhein-Ruhr GmbH, Düsseldorf, Germany.
  • Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.

ORCID-Profile: Tim Sobolevsky, Matthew Fedoruk, Mario Thevis

Zitieren

APA

Sobolevsky, T., Fedoruk, M., Dellanna, F., Geyer, H., Ahrens, B., & Thevis, M. (2025). Long‐Term Excretion of Roxadustat in Urine. Drug Testing and Analysis. https://doi.org/10.1002/dta.3813

Vancouver

Sobolevsky T, Fedoruk M, Dellanna F, Geyer H, Ahrens B, Thevis M. Long‐Term Excretion of Roxadustat in Urine. Drug Testing and Analysis. 2025. doi:10.1002/dta.3813

BibTeX
@article{Sobolevsky2025,
  author = {Sobolevsky, Tim and Fedoruk, Matthew and Dellanna, Frank and Geyer, Hans and Ahrens, Brian and Thevis, Mario},
  title = {Long‐Term Excretion of Roxadustat in Urine},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3813}
}
Kostenlos starten →